Paliperidone palmitate use in pregnancy in a woman with schizophrenia

Arch Womens Ment Health. 2015 Oct;18(5):739-40. doi: 10.1007/s00737-014-0496-6. Epub 2015 Jan 21.

Abstract

Long-acting antipsychotic use in schizophrenia has become an advantage for treatment compliance and convenient administration of the drugs. There is no data on paliperidone palmitate (PP) use in pregnancy, which is the longest-acting (i.e., 1 month) atypical antipsychotic. In this case report, we aim to present a patient diagnosed with schizophrenia who had been using PP before and during her pregnancy until week 28 of gestation and gave birth to a male baby that weighed 3000 g at 39 weeks. As far as we know, this is the first case report on PP use during pregnancy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antipsychotic Agents / administration & dosage*
  • Antipsychotic Agents / therapeutic use
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Intramuscular
  • Male
  • Paliperidone Palmitate / administration & dosage*
  • Paliperidone Palmitate / therapeutic use
  • Pregnancy
  • Pregnancy Complications / psychology
  • Psychiatric Status Rating Scales
  • Schizophrenia / diagnosis
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Paliperidone Palmitate